EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Digital spatial profiling reveals additive effects of triple therapy on tumor microenvironment: anti-PD-L1, anti-VEGF, and PARP inhibition in mouse models

Akihiko Ueda, Ryusuke Murakami, Kentaro Ishida, Kohei Hamada, Jumpei Ogura, Shunsuke Kawahara, Yuka Mise, Yuko Hosoe, Masamichi Sugimoto, Daiko Wakita, Taito Miyamoto, Rin Mizuno und 5 weitere

Cancer Immunology, Immunotherapy · 2026

DOI: 10.1007/s00262-026-04312-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2026. Verfasst von Akihiko Ueda und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology and Obstetrics, Graduate School of Medicine and Faculty of Medicine, Kyoto University, 54 Kawahara-Cho, Shogoin, Sakyo-Ku, K…. Hauptthemen laut MEDLINE: Tumor Microenvironment, Vascular Endothelial Growth Factor A, B7-H1 Antigen, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Immune checkpoint inhibitors show limited efficacy against immune-desert tumors, including ovarian cancer. We investigated triple therapy combining anti-programmed cell death-ligand 1 (PD-L1) antibody, anti-vascular endothelial growth factor (VEGF) antibody, and Poly ADP-ribose polymerase inhibitor (PARPi) on tumor microenvironment using spatial profiling. METHODS: Two mouse models were employed: MC38 (immune-inflamed phenotype) and HM-1 (immune-desert phenotype). MC38 mice received anti-PD-L1 and anti-VEGF as monotherapy or dual combination. HM-1 mice received anti-PD-L1, anti-VEGF, and PARPi as monotherapy, dual combinations (anti-PD-L1 + anti-VEGF, anti-PD-L1 + PARPi, anti-VEGF + PARPi), or triple combination (anti-PD-L1 + anti-VEGF + PARPi). Spatial distribution of immune cells and the tumor microenvironment was analyzed using immunohistochemistry (CD8) and dual immunofluorescence (CD8/Granzyme B) with distance-based density quantification from tumor margins (0 to - 150, - 150 to - 300, - 300 to - 450 μm). High endothelial venule (HEV) formation was evaluated via CD31/MECA79 dual immunofluorescence. RESULTS: MC38 tumors responded to all treatments by day 10. Conversely, HM-1 tumors showed no response at day 10 but responded to two combination therapies by day 20: anti-PD-L1 + anti-VEGF (1.5-fold reduction, p = 0.04) and triple combination therapy (1.7-fold reduction, p = 0.03). In MC38, at - 150 to - 300 μm, anti-PD-L1 + anti-VEGF enhanced CD8 + Granzyme B + cells 1.9-fold versus Control (p = 0.01). In HM-1, at 0 to - 150 μm, triple therapy enhanced CD8 + Granzyme B + cells 2.8-fold (p = 0.02), while anti-PD-L1 + anti-VEGF increased CD8 + Granzyme B + cells 2.5-fold (p = 0.03). Both triple and anti-PD-L1 + anti-VEGF therapies induced CD31 + MECA79 + HEV formation (p < 0.01). CONCLUSIONS: Triple therapy may overcome immune-desert ovarian cancer through additive HEV formation, enhancing cytotoxic CD8 + T cell infiltration into the tumor.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor MicroenvironmentVascular Endothelial Growth Factor AB7-H1 AntigenPoly(ADP-ribose) Polymerase InhibitorsAntineoplastic Combined Chemotherapy ProtocolsImmune Checkpoint InhibitorsOvarian NeoplasmsAnimalsMiceFemaleHumansDisease Models, AnimalCell Line, Tumor

Stichwörter der Autor:innen

Immune checkpoint inhibitorOvarian cancerPARP inhibitorSpatial profilingTumor microenvironmentVEGF inhibition

Substanzen

Vascular Endothelial Growth Factor AB7-H1 AntigenPoly(ADP-ribose) Polymerase InhibitorsImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Gynecology and Obstetrics, Graduate School of Medicine and Faculty of Medicine, Kyoto University, 54 Kawahara-Cho, Shogoin, Sakyo-Ku, Kyoto, 606-8507, Japan.
  • Department of Gynecology and Obstetrics, Graduate School of Medicine and Faculty of Medicine, Kyoto University, 54 Kawahara-Cho, Shogoin, Sakyo-Ku, Kyoto, 606-8507, Japan. ryusukem@kuhp.kyoto-u.ac.jp.
  • Product Research Department, Chugai Pharmaceutical Co., Ltd., Yokohama, Japan.

Zitieren

APA

Ueda, A., Murakami, R., Ishida, K., Hamada, K., Ogura, J., Kawahara, S., Mise, Y., Hosoe, Y., Sugimoto, M., Wakita, D., Miyamoto, T., Mizuno, R., Taki, M., Yamanoi, K., Yamaguchi, K., Hamanishi, J., & Mandai, M. (2026). Digital spatial profiling reveals additive effects of triple therapy on tumor microenvironment: anti-PD-L1, anti-VEGF, and PARP inhibition in mouse models. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04312-3

Vancouver

Ueda A, Murakami R, Ishida K, Hamada K, Ogura J, Kawahara S, et al. Digital spatial profiling reveals additive effects of triple therapy on tumor microenvironment: anti-PD-L1, anti-VEGF, and PARP inhibition in mouse models. Cancer Immunology, Immunotherapy. 2026. doi:10.1007/s00262-026-04312-3

BibTeX
@article{Ueda2026,
  author = {Ueda, Akihiko and Murakami, Ryusuke and Ishida, Kentaro and Hamada, Kohei and Ogura, Jumpei and Kawahara, Shunsuke and Mise, Yuka and Hosoe, Yuko and Sugimoto, Masamichi and Wakita, Daiko and Miyamoto, Taito and Mizuno, Rin and Taki, Mana and Yamanoi, Koji and Yamaguchi, Ken and Hamanishi, Junzo and Mandai, Masaki},
  title = {Digital spatial profiling reveals additive effects of triple therapy on tumor microenvironment: anti-PD-L1, anti-VEGF, and PARP inhibition in mouse models},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  doi = {10.1007/s00262-026-04312-3}
}
Kostenlos starten →